Novelgen
Find Us
← Back to list

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease

BioPharma DiveBen FidlerNovember 19, 2026
The product of a collaboration with Alnylam, Livsayis is now Regeneron s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.
Read original article
← Back to list